FDA Expands Imiglucerase Indications to Include Type 3 Gaucher Disease, All Ages The FDA has expanded the indications for imiglucerase, making it the first approved therapy for non-CNS symptoms of type 3 GD.

The @fda.gov approved #Imiglucerase (#Cerezyme®) for the treatment of non-central nervous system (CNS) manifestations of both type 1 and type 3 #GaucherDisease (GD), making it the first and only approved therapy for non-CNS symptoms of type 3 GD.

Read more: https://bit.ly/4t1k8Um

#RareDisease